Muted Demand Keeps Jyothy Labs Stock Far from Its Highs

reported a steady Q2FY26 with flat YoY sales growth and a 3% volume increase, slightly below estimates. The gap between value and volume growth came from MRP cuts, higher grammage, and promotional offers across key categories. The company expects a 2%-2.5% value-volume gap ahead. While alternate channels delivered double-digit growth, the GT channel continued to face pressure. In contrast to the broader market strength and the strong uptrend in Nifty Pharma, the stock has been unable to recover. Jyothy Labs remains under stress at lower levels, down nearly 28% from its 52-week high and around 48% below its all-time high touched in September 2024, reflecting sustained weakness in sentiment. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.